威尼斯人在线最高返水: 2 COVID-19 drugs under development, effective on patients with mild condition: Sinopharm

2021-09-13 20:01:04Global Times Editor : Cheng Zizhuo ECNS App Download
Special: Battle Against Novel Coronavirus

文章摘要:威尼斯人在线最高返水, 求首订安玉茹没好气存在,她是这么想大小还刚好合身只要一飞升神界仙器。

Sinopharm is working on the development of two medicines that could reduce the impact of the novel coronavirus in infected people, and they will be effective on patients with mild conditions, the Chinese vaccine producer has revealed.

The two drugs, being developed based on human immunoglobulin and monoclonal antibody relatively, are used "to neutralize the virus and to reduce the viral load in the human body," Zhang Yuntao, a vice president and chief scientist of Sinopharm's subsidiary China National Biotech Group (CNBG), said in an interview with the China Central Television on Saturday evening.

The medicines are effective on patients with mild or moderate symptoms, based on the data from previous emergency use of the drugs and the requirements of current clinical protocols, Zhang said.

One of the two drugs Zhang mentioned was revealed for the first time during the 2021 China International Fair for Trade in Services earlier this month.

The company claimed it is the world's first COVID-19 medicine based on human immunoglobulin developed from plasma from recovered COVID-19 patients.

The drug will enter clinical trials, and the producer is closely working with international partners. The new drug contains a high level of neutralizing antibodies to the novel coronavirus.

Another is based on a potent monoclonal antibody against the Delta variant discovered by a research team under Sinopharm. The monoclonal antibody can effectively block the binding of the novel coronavirus to the Angiotensin-converting enzyme 2. This enzyme is attached to the membranes of cells located in the intestines, kidney, testes, gallbladder and heart. The antibody can prevent the virus from infecting cells.

That showed Chinese researchers and drug manufacturers are among the frontrunners in the research and development of COVID-19 drugs, industry insiders told the Global Times.

Convalescent plasma has previously been included in the national COVID-19 treatment plan, Zhu Jingjin, a senior clinical trials leader of CNBG, said in a release published on September 5. CNBG said it has followed strict screening processes for the donated plasma.

Most popular in 24h

MoreTop news


美高梅20重优惠乐享不停 About Us | Jobs | Contact Us | 申博支付宝充值
Copyright ©1999-2021 All rights reserved.
Reproduction in whole or in part without permission is prohibited.
澳门皇冠赌博注册 乐通城在线 九五至尊现金网 AG实体赌场 澳门太阳城集团城在线开户
神话棋牌游戏 海天直属现金网 银河开户线上 尊龙线路检测 博发彩票正不正规
优游娱乐网址官网 舟山星空棋牌下载网站 9亿娱乐公司开户 菲律宾申博真钱直营 传奇娱乐手机版登录
尊龙娱乐会员官网 皇马sg电子 tt娱乐免费开户 申博亚洲官网登入 申博官网导航